Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland and Nursing Science, Department of Public Health, Faculty of Medicine, University of Basel, Basel, Switzerland.
Department of Nursing, Inselspital, Bern University Hospital, Bern, Switzerland and Nursing Science, Department of Public Health, Faculty of Medicine, University of Basel, Basel, Switzerland.
Eur J Oncol Nurs. 2021 Aug;53:101997. doi: 10.1016/j.ejon.2021.101997. Epub 2021 Jun 25.
The aims of this study are to assess symptoms, health-related quality of life (HRQoL) and associations between symptoms and HRQoL in adult patients with myeloma or lymphoma undergoing autologous stem-cell transplantation (ASCT) during the pre- and post-transplantation phases in the outpatient setting.
This longitudinal, observational study conducted at a Swiss tertiary care hospital assesses the prevalence, frequency, severity and distress of symptoms, as well as HRQoL prior to hospital admission (T1), within two weeks after hospital discharge (T2) and three months after hospital discharge (T3). The study uses an adapted version of the Memorial Symptom Assessment Scale and the Functional Assessment of Cancer Therapy - Bone Marrow Transplant. Correlations between symptoms and HRQoL are explored.
The total cohort included 47 patients. Participants experienced the highest mean number of symptoms (7.58, SD ± 2.67) within two weeks after hospital discharge. At T1, participants reported a mean of 6.29 (SD ± 2.49) symptoms, and 5.28 (SD ± 2.42) at T3. Lack of energy, numbness/tingling in hands/feet and pain were the most prevalent and distressing symptoms. The overall HRQoL scores varied only moderately (range 0-188); mean HRQoL scores were 142.95 (SD ± 21.06) at T1, 139.87 (SD ± 21.92) at T2 and 147.54 (SD ± 23.27) at T3. No significant correlations were found between symptoms and HRQoL.
Because of the high symptom prevalence during the first few weeks after hospital discharge, a systematic symptom assessment in this period is needed with the aim of intervening at an early stage and reducing the patient's symptom burden.
本研究旨在评估接受自体干细胞移植（ASCT）的骨髓瘤或淋巴瘤成年患者在门诊环境下移植前和移植后的过渡期内的症状、健康相关生活质量（HRQoL）以及症状与 HRQoL 之间的相关性。
这项在瑞士三级护理医院进行的纵向观察性研究评估了在入院前（T1）、出院后两周内（T2）和出院后三个月（T3）的症状流行率、频率、严重程度和困扰程度，以及 HRQoL。研究采用了改良版的 Memorial 症状评估量表和癌症治疗功能评估-骨髓移植。还探索了症状与 HRQoL 之间的相关性。
总队列包括 47 名患者。患者在出院后两周内经历的平均症状数最多（7.58，标准差 ± 2.67）。在 T1 时，患者报告的平均症状数为 6.29（标准差 ± 2.49），在 T3 时为 5.28（标准差 ± 2.42）。乏力、手脚麻木/刺痛和疼痛是最常见和最困扰的症状。整体 HRQoL 评分变化不大（范围 0-188）；T1 时的平均 HRQoL 评分为 142.95（标准差 ± 21.06），T2 时为 139.87（标准差 ± 21.92），T3 时为 147.54（标准差 ± 23.27）。未发现症状与 HRQoL 之间存在显著相关性。
由于出院后最初几周内症状的高流行率，在此期间需要进行系统的症状评估，以便尽早干预，减轻患者的症状负担。
